Cutaneous Larva Migrans

Cutaneous larva migrans (CLM) is one of the tropical diseases that often causes major health issues in especially travelers and inhabitants of endemic regions. Our company is at the forefront of developing novel vaccines and therapeutics for CLM. We leverage cutting-edge technologies and a deep understanding of parasitic diseases to create effective solutions.

Overview of Cutaneous Larva Migrans

Cutaneous larva migrans (CLM) is a zoonotic infection caused by A. braziliense most commonly acquired from soil and sand into which these parasites have been shed. There is a high possibility of infection during travel to tropical as well as subtropical regions. It is often self-limiting as the larvae enter the body through skin, leading to severe pruritus and serpentine eruptions on the skin but have no life threatening effects. While CLM does not endanger a person's life, its symptoms can be bothersome and may lead to self-inflicted infections as a consequence of itching.

Fig.1 The life cycle of Cutaneous larva migrans. (Source: Centres for Disease Control and Prevention)

Vaccine Development for Cutaneous Larva Migrans

At the moment, there are no valid vaccines that prevent cutaneous larva migrans. Creating a vaccine poses many hurdles owing to the intricate life cycle of organisms that cause this disease, as well as the specific immune response that needs to be targeted. However, evaluation of possible vaccine options is being conducted with a focus on the following areas:

Antigen Identification: The development of a vaccine pivots on the existence of any specific antigens that may trigger a protective immune response in human beings. Researchers have identified proteins produced from the Secreted Ancylostoma larvae which have the potential to enhance immune evasion. For formulation of subunit vaccines that might provide protection against CLM, research on immunogenic aspects of these proteins must be conducted.

DNA Vaccines: One of the modern strategies for combating CLM is DNA vaccination. Plasmids containing specific Ancylostoma antigens are expected to initiate a strong immune response among the target individuals. This technique has been proven effective against other parasitic infections, like Metastrongylias, and may be tailored to work on CLM. For instance, within the species of animals, preliminary research have confirmed that DNA vaccines are protective, and therefore, human trials can be pursued.

Therapeutics Development for Cutaneous Larva Migrans

• Oral Antihelminthics
  The most-used medication for CLM today are the oral anti-helminthic drugs taken orally. These drugs work by either inhibiting metabolism in one way or by or feeding in copulation.
  Broad-ranged antiparasitic Ivermectin has been found to be effective against CLM. Another used antihelminthic along with Ivermectin is albendazole. Both are well-known for CLM therapeutic because they are effective in diminishing the load of larvae.
• Topical Therapeutics
  The use of oral drugs are limited for some patients due to their contraindications, consequently the use of CLM's topical therapies are on the rise.
  Studies done recently experimented the use of topical hingegen Ivermectin. Some reduction in the larval tracks was observed. This route of administration could offer better therapeutic effects with lower invasiveness.

Therapeutic Development

Preclinical Research

Pathogen and Host Research

Disease Model Development

Our Services

Through the use of active research and development within the company, we are dedicated towards finding new solutions within the pharmaceutical industry. As we move further in our mission we will continue to work with more unique approaches in creating vaccines and other therapeutics. That allows to keep the first place in researching new drugs for infections diseases.

Vaccine Development

• Live-attenuated Vaccine
• Inactivated Vaccine
• Toxoid Vaccine
• Viral Vector Vaccine
• Virus-like Particles Vaccine
• Protein Subunit Vaccine
• mRNA Vaccine
• DNA Vaccine

Therapeutic Development

• Small Molecule Drug Development Services
• Therapeutic mRNA Development Services
• Therapeutic Antibody Development Services
• Cell Therapy Development Services

Disease Models

• Uncinaria stenocephala Infection Animal Models
• Bunostomum phlebotomum Infection Animal Models
• Ancylostoma ceylonicum Infection Animal Models

Our preclinical research services include comprehensive antigen screening and validation to identify potential vaccine candidates. We use advanced bioinformatics tools and wet-lab techniques to evaluate antigen potential. If you are interested in our services, please feel free to contact us.

All of our services and products are intended for preclinical research use only and cannot be used to diagnose, treat or manage patients.